Navigation Links
Discovery Labs Reports Third Quarter 2012 Financial Results
Date:11/8/2012

cluding projections of future cash balances and anticipated cash outflows, to differ materially from the statements made.  Examples of such risks and uncertainties are: risks relating to Discovery Labs' efforts to successfully commercialize SURFAXIN and AFECTAIR, including: (i) whether Discovery Labs' products will meet the requirements to be included in the hospitals' purchasing lists of approved drug products, medical devices and equipment, (ii) whether Discovery Labs' products will gain market acceptance and healthcare professionals will recognize the perceived advantages over the currently available products, (iii) whether Discovery Labs will succeed in introducing its products using its own commercial and medical affairs organizations; (iv) whether Discovery Labs will be successful in completing development of, and introducing, its planned second vial size for SURFAXIN and follow-on AFECTAIR devices; and (v) even if Discovery Labs is successful in commercializing its products, whether its products will be profitable and whether the revenues generated will be sufficient to fund Discovery Labs' research and development activities and support its operations; risks that Discovery Labs may be unable in a timely manner, if at all, (i) to identify potential strategic partners or collaborators to support development of its products and, if approved, commercialize its products in markets outside the U.S., (ii) to access its committed equity financing facility (CEFF), or (iii) to raise additional capital to fund its activities, or that additional financings could result in substantial equity dilution; risks related to Discovery Labs' research and development activities, including time-consuming and expensive pre-clinical studies, clinical trials, which may be subject to potentially significant delays or regulatory holds, or fail, and the need for sophisticated and extensive analytical methodologies; risks related to technology transfers to contract manufac
'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
4. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
5. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
7. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
8. AMRI Further Expands Discovery Capabilities in India
9. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
10. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
11. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Medtronic,s roughly $43 billion acquisition and ... in the media for its US Federal tax ... player in one of the fastest growing device ... research firm said  the two companies compete in ... of solutions spanning inpatient to home care, and ...
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Youngsters who enter ... new study suggests. Early puberty was linked with ... poor self-image and high anxiety levels, according to the ... such as conflict with family and peers, and having ... study found. Although the study found an association ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/26/2014)... Randy Dotinga HealthDay Reporter ... drugs such as Prilosec and Nexium may disrupt the makeup ... of infections and other problems, a small new study suggests. ... it more likely users will become ill, and study authors ... inhibitors. However, these antacids "should be used at the ...
Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Weight Watchers,International, Inc. (NYSE: WTW ) will release ... close on Thursday, July 31, 2008., The Company ... at 5:00,p.m. ET. During the conference call, David Kirchhoff, ... Officer, will discuss,second quarter results and answer questions from ...
... its,efforts to ensure the State,s leaders are putting patients ... for Patient Care (CPC), a,non-profit, patient-advocacy organization, hand delivered ... as other key leaders in the,State Legislature today., ... with a better,understanding of how devastating these massive health ...
... be done without destroying embryo , , WEDNESDAY, July 9 ... in developing human embryonic stem cells earlier in the ... embryo, so the whole embryo is not destroyed. , ... European Society of Human Reproduction & Embryology annual conference ...
... Pain Centers (SCPC) have been shown to perform better ... for Medicare and Medicaid Services (CMS) as compared to ... an Emory University researcher. , The findings, ... for observation medicine in the Emory University School of ...
... Holdings, Inc.,(NYSE and SWX: ZMH) announced today its second ... live over the Internet on,Thursday, July 24, 2008, at ... results will be made available at 7:00 a.m. the,morning ... can be accessed via Zimmer,s Investor Relations,website at ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:Weight Watchers Announces Second Quarter 2008 Earnings Conference Call 2Health News:CPC Hand-Delivers Patient Testimonies to State Leaders Pleading for No Budget Cuts to Health and Human Services 2Health News:New Technique Harvests Stem Cells at Earlier Stage 2Health News:New Technique Harvests Stem Cells at Earlier Stage 3Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
... proBNP assay is a rapid and accurate bedside ... system assisting the diagnosis and assessment of patients ... both speed and accuracy profit from ... proBNP assay = 12 minutes. In emergency departments ...
Medicine Products: